Amgen Files Lawsuit Challenging Colorado Price Cap for Arthritis Drug

By Editorial Team

Amgen has once again taken legal action against Colorado over its price cap for the arthritis drug Enbrel. The pharmaceutical company claims that Colorado’s drug price-control statute violates the U.S. Constitution, conflicts with federal patent law, and poses a threat to patients’ access to essential medications.

The lawsuit, filed in the United States District Court for the District of Colorado, alleges that the state’s pricing regulations hinder innovation and investment in life-saving drugs. Amgen is represented by the law firm King & Spalding in this legal battle.

This legal dispute highlights the ongoing tension between state efforts to control drug prices and pharmaceutical companies’ concerns about the impact on their ability to recoup research and development costs.

Amgen’s challenge to Colorado’s price cap for Enbrel underscores the complex legal landscape surrounding drug pricing regulations and the broader implications for the healthcare industry.